Fresenius SE & Co. KGaA (FSNUF)
OTCMKTS
· Delayed Price · Currency is USD
37.73
-3.28 (-8.00%)
At close: Apr 7, 2025
Fresenius SE & Co. KGaA Revenue
Fresenius SE & Co. KGaA had revenue of 5.65B EUR in the quarter ending March 31, 2025, with 5.63% growth. This brings the company's revenue in the last twelve months to 22.13B, up 4.61% year-over-year. In the year 2024, Fresenius SE & Co. KGaA had annual revenue of 21.83B with 3.64% growth.
Revenue (ttm)
22.13B EUR
Revenue Growth
+4.61%
P/S Ratio
1.15
Revenue / Employee
125.42K EUR
Employees
176,486
Market Cap
27.60B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.83B | 766.00M | 3.64% |
| Dec 31, 2023 | 21.07B | -465.00M | -2.16% |
| Dec 31, 2022 | 21.53B | -15.99B | -42.61% |
| Dec 31, 2021 | 37.52B | 1.24B | 3.43% |
| Dec 31, 2020 | 36.28B | 868.00M | 2.45% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
| American Oncology Network | 1.76B |
Fresenius SE & Co. KGaA News
- 23 days ago - Fresenius medical care outlines 2025 operating income growth targets amid strategic transformations - Seeking Alpha
- 23 days ago - Fresenius SE & Co. KGaA 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 23 days ago - Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Fresenius SE & Co. KGaA reports Q1 results - Seeking Alpha
- 24 days ago - Fresenius posts profit beat in first quarter, confirms outlook - Reuters
- 4 weeks ago - Fresenius: Holding On For Longer-Term Growth Driven By Demand In Kidney Care Segment - Seeking Alpha
- 7 weeks ago - Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps - Benzinga
- 7 weeks ago - Pacira surges on patent settlement with Fresenius - Seeking Alpha